Bioventus Inc.
No enriched coverage for $BVS in the last 7 days.
No SEC Form 4 filings for $BVS in the last 30 days.
See all $BVS insider activity →Bioventus (BVS) held its Q2 2026 earnings call, reporting Q2 revenue up 4%, with double-digit growth in Pain Treatments led by DUROLANE. The company reiterated full-year guidance, citing adjusted EBITDA margin of 23% and adjusted EPS of $0.22 for the quarter. Cash from operations was $20M, with net leverage reduced below 2x.
A dpa-AFX report says Bioventus (BVS), Trevi Therapeutics (TVTX), Odonate Therapeutics (ODTX) and Corcept? (CRL) hit 52-week highs on Aug. 5, 2026, after positive Q2 results. It also references Aclaris Therapeutics (ACRS) in the same context.
Bioventus Inc. (BVS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bioventusex-991q22026.htm EX-99.1 Document Exhibit 99.1 Bioventus Reports Second Quarter Financial Results • Q2 reported revenue of $153.2 million increased 4% • Q2 GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted
Recent BVS coverage spans market movers, earnings and financial news.
The call combines reaffirmed guidance with a strategic review process, which can raise deal-optionality risk while supporting near-term fundamentals.
The article frames BVS strength as earnings-driven, suggesting near-term momentum tied to its latest quarter.
The 8-K combines an earnings and guidance reaffirmation with a potential M&A or strategic outcome review, increasing event risk and optionality.
The stock breakout is supported by quantified earnings expectations and recent revenue growth, but the article does not indicate a newly released guidance update.
Improving revenue and defined EPS outlook can support valuation, especially if pain-management demand trends persist.
alphai scores every news story that mentions BVS with an AI model for sentiment and relevance, and aggregates insider trades from Bioventus Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Bioventus (BVS) held its Q2 2026 earnings call, reporting Q2 revenue up 4%, with double-digit growth in Pain Treatments led by DUROLANE. The company reiterated full-year guidance, citing adjusted EBITDA margin of 23% and adjusted EPS of $0.22 for the quarter. Cash from operations was $20M, with net leverage reduced below 2x.
4 min readA dpa-AFX report says Bioventus (BVS), Trevi Therapeutics (TVTX), Odonate Therapeutics (ODTX) and Corcept? (CRL) hit 52-week highs on Aug. 5, 2026, after positive Q2 results. It also references Aclaris Therapeutics (ACRS) in the same context.
4 min readBioventus Inc. (BVS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bioventusex-991q22026.htm EX-99.1 Document Exhibit 99.1 Bioventus Reports Second Quarter Financial Results • Q2 reported revenue of $153.2 million increased 4% • Q2 GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted
6 min readBiotech shares hit 52-week highs on July 28, 2026. Incyte (INCY) rose over 9% to $132.58 after Q2 revenue of $1.67B, up 38% year over year, and raised full-year net sales guidance to $5.13B-$5.26B. Pulse Biosciences (PLSE) gained over 8% to $36.29. Other climbers included Shoulder Innovations (SI), Bioventus (BVS), and LB Pharmaceuticals (LBRX).
4 min readBiotech stocks hit 52-week highs on July 16, 2026 ahead of quarterly reports or a conference. CareDx (CDNA) rose to a 52-week high of $40.38% and reported Q1 revenue of $118M. Integra LifeSciences (IART) reached $20.26, with Q1 revenue $391.9M. Bioventus (BVS) hit $12.53, Q1 revenue $132M. Enliven Therapeutics (ELVN) hit $53.89 after a ~$460M public offering.
5 min readBioventus said its peripheral nerve stimulation (PNS) product is gaining attention after Boston Scientific and Medtronic acquisitions of competitors, and management estimates the PNS market at ~$250M growing nearly 25% annually. The company is also investing in PRP using its existing HA sales force. Bioventus reported Q1 revenue up 7% and EBITDA up ~25% y/y; EPS doubled. It reduced leverage to just over 2x and expects PNS+PRP to add 200 bps to full-year growth, with stronger 2H contribution.
5 min readFNArena’s daily ASX300 “winners and losers” table ranks the 20 biggest percentage gainers and decliners by end-of-day moves, using automated raw data and excluding low-liquidity stocks via a volume filter. Reported gainers include OML (+9.56%) and CHN (+5.88%); decliners include CHN (-10.39%) and PDN (-8.78%). The outlet says it’s for information only, not investment advice.
1 min readBioventus (BVS) reported Q1 2026 revenue up 7% year over year, slightly above expectations, citing strong core portfolio performance and strategic investments. Adjusted EBITDA rose 24% and margin improved by 200+ bps; adjusted EPS doubled to $0.15. The company raised full-year adjusted EPS guidance to $0.75–$0.79 and expects higher cash from operations. It ended with $36M cash and reduced debt by $22M.
6 min readBioventus Inc.'s Senior Vice President and CFO, Mark Leonard Singleton, exercised 13,000 restricted stock units (RSUs) on April 10, 2026, receiving an equal number of Class A shares. To cover tax obligations, 5,648 Class A shares were withheld at a price of $9.06 per share in a non-market transaction. Following these transactions, Singleton directly owns 182,981 Class A shares, indicating a net increase in his equity position.
2 min readThis article reports on an insider trading activity for Bioventus Inc. (BVS) where Katrina J. Church, SVP & Chief Compliance Officer, exercised restricted stock units on April 10, 2026. She received 4,300 shares of Class A common stock and 1,868 shares were withheld to cover tax obligations. Post-transaction, her direct ownership increased to 64,164 shares, reflecting a routine equity compensation event rather than a discretionary market trade.
2 min read
